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Background: Seasonal variation in respiratory illnesses and
exacerbations in pediatric populations with asthma is well
described, though whether upper airway microbes play seasonspecific roles in these events is unknown.
Objective: We hypothesized that nasal microbiota composition
is seasonally dynamic and that discrete microbe–host
interactions modify risk of asthma exacerbation in a seasonspecific manner.
Methods: Repeated nasal samples from children with
exacerbation-prone asthma collected during periods of
respiratory health (baseline; n 5 181 samples) or first captured
respiratory illness (n 5 97) across all seasons, underwent
bacterial (16S ribosomal RNA gene) and fungal (internal
transcribed spacer region 2) biomarker sequencing. Virus
detection was performed by multiplex PCR. Paired nasal
transcriptome data were examined for seasonal dynamics and
integrative analyses.
Results: Upper airway bacterial and fungal microbiota and
rhinovirus detection exhibited significant seasonal dynamics. In
seasonally adjusted analysis, variation in both baseline and
respiratory illness microbiota related to subsequent
exacerbation. Specifically, in the fall, when respiratory illness
and exacerbation events were most frequent, several Moraxella
and Haemophilus members were enriched both in virus-positive
respiratory illnesses and those that progressed to exacerbations.
The abundance of 2 discrete bacterial networks,
characteristically comprising either Streptococcus or
Staphylococcus, exhibited opposing interactions with an
exacerbation-associated SMAD3 nasal epithelial transcriptional
module to significantly increase the odds of subsequent
exacerbation (odds ratio 5 14.7, 95% confidence interval 5
1.50-144, P 5 .02; odds ratio 5 39.17, 95% confidence
interval 5 2.44-626, P 5 .008, respectively).
Conclusions: Upper airway microbiomes covary with season
and with seasonal trends in respiratory illnesses and asthma
exacerbations. Seasonally adjusted analyses reveal specific
bacteria–host interactions that significantly increase risk of
asthma exacerbation in these children. (J Allergy Clin Immunol
2022;nnn:nnn-nnn.)
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Abbreviations used
ITS2: Internal transcribed spacer region 2
OR: Odds ratio
OTU: Operational taxonomic unit
PERMANOVA: Permutational analysis of variance
RNA-Seq: RNA sequencing
rRNA: Ribosomal RNA
RV: Rhinovirus
SMAD3: Mothers against decapentaplegic homolog 3

Incidence of asthma exacerbation is seasonal and a leading cause
of pediatric morbidity.1 The annual peak in the United States is typically observed in the fall (September through November), with

some variation by geographical region.2 Seasonal variability in
acute asthma exacerbations requiring hospitalization is also
strongly associated with age and is more likely to vary by season
in younger children.3 Asthma exacerbations track with seasonal trajectories of viral upper respiratory infections.4 Approximately 80%
of acute asthma exacerbations in children present with a cooccurring respiratory virus, with rhinovirus (RV) accounting for 60%
to 70% of virus infection–associated exacerbations.5 Thus, understanding upper airway factors that covary with season and potentiate these clinical respiratory events may offer opportunities to
prevent or modify their incidence.
Recent studies have revealed relationships among distinct
upper airway microbiota, virus infections, and risk of asthma
exacerbations, suggesting that interactions between the upper
airway microbiome and airway mucosal responses may influence
susceptibility to these respiratory events.6,7 Specific bacterial
genera dominate distinct upper airway microbiota structures,
with those dominated by Moraxella catarrhalis, Streptococcus
pneumoniae, or Haemophilus influenzae emerging across multiple independent studies as associated with age6 and RVassociated asthma exacerbation.6,7 Further, longitudinal studies
of pediatric populations without asthma have identified seasonal
relationships among upper airway microbiota composition, viral
upper respiratory infection, and sinusitis.8,9 These data suggest
that the upper airway microbiota is dynamically responsive to
seasonal variation and could explain the heightened seasonal susceptibility to respiratory illness and exacerbation events in populations of children with asthma.
Airway immune responses clearly contribute to the relationship between upper respiratory infections and asthma exacerbations.10 Using nasal epithelial transcriptional analysis, we
previously identified specific gene expression modules (groups
of coexpressed genes), which are differentially regulated during
viral and nonviral exacerbations, including upregulation of those

WebMD/Medscape, Sanofi, Vectura, and Circassia. J. E. Gern reports consulting fees
from Janssen, Regeneron, and PReP Biosciences and travel expenses from BoehringerIngelheim. W. W. Busse reports consulting fees from Boston Scientific, ICON,
Novartis, GlaxoSmithKline, Genentech, Roche, Boehringer-Ingelheim, Sanofi Genzyme, AstraZeneca, Teva, 3M, PrEPBiopharm, Circassia, Regeneron, Peptinnovate,
and Elsevier. D. J. Jackson reports consulting fees from Novartis, GlaxoSmithKline,
Boehringer-Ingelheim, Pfizer, Commense, and Vectura and a grant from NIH/NHLBI.
S. V. Lynch reports grants from the NIH/National Institute of Allergy and Infectious
Diseases, NIH/National Institute on Drug Abuse, NIH/Eunice Kennedy Shriver
National Institute of Child Health and Human Development, NIH/Office of the
Director, and the Crohn’s and Colitis Foundation of America; reports personal fees
from Siolta Therapeutics outside the submitted work; has a patent ‘‘Reductive prodrug
cancer chemotherapy (Stan449-PRV)’’ issued, a patent ‘‘Combination antibiotic and
antibody therapy for the treatment of Pseudomonas aeruginosa infection
(WO2010091189A1)’’ with royalties paid by KaloBios, a patent ‘‘Therapeutic microbial consortium for induction of immune tolerance’’ licensed to Siolta Therapeutics, a
patent ‘‘Systems and methods for detecting antibiotic resistance

(WO2012027302A3)’’ issued, a patent ‘‘Nitroreductase enzymes (US7687474B2)’’ issued, a patent ‘‘Sinusitis diagnostics and treatments (WO2013155370A1)’’ licensed by
Reflourish, and a patent ‘‘Methods and systems for phylogenetic analysis
(US20120264637A1)’’ issued; and is a cofounder of Siolta Therapeutics, a start-up
developing a mixed-species microbial oral therapeutic for induction of immune tolerance. The rest of the authors declare that they have no relevant conflicts of interest.
Received for publication November 16, 2021; revised January 7, 2022; accepted for publication January 27, 2022.
Corresponding author: Susan V. Lynch, PhD, Department of Medicine, University of California, San Francisco, 513 Parnassus Ave 357D, San Francisco, CA 94143. E-mail:
susan.lynch@ucsf.edu. Matthew C. Altman, MD, MPH, Systems Immunology Program, Benaroya Research Institute, 1201 Ninth Avenue, Seattle, WA 98101 E-mail:
maltman@benaroyaresearch.org.
0091-6749/$36.00
Ó 2022 Published by Elsevier Inc. on behalf of the American Academy of Allergy,
Asthma & Immunology
https://doi.org/10.1016/j.jaci.2022.01.020

Key words: Microbiome, respiratory illness, transcriptomics, pediatric asthma, exacerbations, virus infection

Downloaded for Anonymous User (n/a) at Henry Ford Hospital / Henry Ford Health System (CS North America) from ClinicalKey.com by
Elsevier on March 07, 2022. For personal use only. No other uses without permission. Copyright ©2022. Elsevier Inc. All rights reserved.

MCCAULEY ET AL 3

J ALLERGY CLIN IMMUNOL
VOLUME nnn, NUMBER nn

involved in cell differentiation and wound healing, eosinophil
activation and mucus hypersecretion, extracellular matrix production, and epidermal growth factor receptor signaling.10
Collectively, these findings support the concept that viruses,
type II inflammatory immune responses, epithelial integrity, and
upper airway microbiota represent important and potentially
interactive contributors to asthma exacerbations.
We therefore hypothesized that the upper airway microbiota is
dynamic and covaries with season. We further postulated that
season- and age-aware algorithms are necessary to uncover
relationships between upper airway microbiota and respiratory
illness or exacerbation events in children with asthma. Using
longitudinal nasal samples collected from participants in the
MUPPITS-1 study of urban-residing children (6-17 years old)
with exacerbation-prone asthma, we found that the upper airway
microbiome indeed exhibits seasonal dynamics. Further, by
leveraging seasonally adjusted analyses, we uncovered networks
of upper airway microbes that interact with epithelial transcriptional modules during respiratory illness events to significantly
increase risk of subsequent exacerbation.

Deep Sea saline nasal spray was administered into one nostril, and the child
expelled the liquid from the nostril into a small plastic bag, then repeated in the
opposite nostril. After the procedure, 1.5 mL of Addipak sterile saline
(Hudson RCI, Temecula, Calif) was added to the bag, and the sample was
mixed in and maintained in the refrigerator for additional processing within 24
hours. During additional processing, the sample was transferred completely
from the plastic bag into M4RT viral transport media (Thermo Fisher
Scientific, Waltham, Mass) and vortexed vigorously for 1 minute; 500 mL
was formed into aliquots for virus analysis at the University of Madison. Subsequently, 1000 mL was formed into aliquots in 3 tubes stored on site, 1 aliquot
of which was shipped to the University of California, San Francisco, for 16S
rRNA and ITS2 biomarker sequencing.

Virus detection and specification
Respiratory viruses were assessed in nasal mucus samples obtained by the
above-described nasal blow technique at respiratory illness events as previously described11 using multiplex PCR, including the identification of all common respiratory viruses. Partial sequencing of RV allowed for further
classification into species and types.12

Nasal 16S rRNA gene and ITS2 sequencing
METHODS
Samples obtained from children enrolled onto the Mechanisms Underlying
Asthma Exacerbations Prevented and Persistent with Immune-based therapy
(MUPPITS-1; NCT02502890) trial were used for this study, which was part
of the Inner-City Asthma Consortium.10 Children enrolled onto this study lived
in 1 of 9 inner-city study sites in the United States within Boston, Chicago, Cincinnati, Dallas, Denver, Detroit, New York, St Louis, and Washington, DC;
were between 6 and 17 years old; had doctor-diagnosed asthma; had experienced at least 2 exacerbations in the previous year; and had eosinophil counts
greater than 150 cells/mm3. In addition, eligible participants required treatment with at least 1 puff twice daily of either fluticasone 250 mg or fluticasone/salmeterol (Advair, Glaxo Smith Klein, Middlesex, United Kingdom)
250/50 mg for those less than or greater than 12 years old, respectively, and
were nonsmokers. Children provided an initial baseline visit sample at enrollment and were then observed for upper respiratory illness symptoms and
asthma exacerbations for either 6 months or 2 respiratory illness visits, whichever came first. Exacerbations were defined as a need for systemic corticosteroid therapy or hospitalization.
A clinic visit with nasal sampling occurred within 3 days of the start of
reported upper respiratory illness symptoms for each illness (V1a and V2a,
respectively). For this study, baseline and V1a samples were used. For each
illness event, a subsequent asthma exacerbation was recorded if there was a
requirement for systemic corticosteroids up to 10 days after the onset of
respiratory illness symptoms. Nasal mucus samples collected at baseline and
V1a were processed for microbiota (16S ribosomal RNA [rRNA] and internal
transcribed spacer region 2 [ITS2] analyses); nasal lavage samples collected in
parallel underwent RNA sequencing (RNA-Seq) analyses as previously
described.10 Predefined exacerbation-associated transcriptional modules identified in the parent study10 were used in this investigation. In brief, gene
expression data were clustered using weighted correlation network analysis
into modules. These modules were then annotated using the Database for
Annotation, Visualization, and Integrated Discovery. STRING identified
known or predicted protein–protein interactions. Summary annotations for
each module were derived from a manual inspection of a module’s cell type
assignment, functional enrichments, and interaction network.
This study was approved by the institutional review boards of all
institutions. All participants or their legal guardians provided written informed
consent before enrollment onto the study.

Nasal blow collection and processing
The sample collection protocol was developed by the Inner-City Asthma
Consortium. Samples were collected under the supervision of a physician.

Nasal blow samples obtained at baseline and respiratory illness clinic visits
underwent 16S rRNA gene and ITS2 sequencing. DNA was extracted from all
samples using a modified cetyltrimethylammonium bromide buffer extraction
protocol as previously described.13 Extracted DNA was amplified for the 16S
rRNA gene V4 region using 515F and 806R primer pairs as previously
described by Caporaso et al.14 After sequencing on the NextSeq 500 platform
(Illumina, San Diego, Calif), bacterial reads were demultiplexed by barcode
and then assembled using FLASH v1.2.7,15 and low-quality reads were discarded using QIIME 1.9.1.16 Sequences with more than 2 consecutive bases
having a Q-score of less than 30 were truncated. Sequences were dereplicated
and binned into operational taxonomic units (OTUs) using a 97% sequence
similarity threshold using USEARCH.17 OTUs were removed if they were
determined to be chimeric or of nonbacterial origin using QIIME. Negative
controls provided information about background signal, and OTUs were
removed if they were in more than half of negative controls and most of the
samples. Any remaining negative control read counts were subtracted from
samples using the maximum read count across negative controls. Upper airway
bacterial sequence data were representatively rarefied at 20,722 reads per sample, a level selected to optimize sample count and community coverage.
Using extracted DNA, ITS2 of the rRNA gene was also amplified using
fITS7 and ITS4, designed for the Illumina MiSeq platform and processed as
previously described.18 Fungal microbiota sequence data underwent similar
procedures after sequencing with the following modifications. Adapter sequences were removed and sequences were quality trimmed using ‘cutadapt’19 before assembling paired-end reads with FLASH. ITSx extractor
was used to identify sequences as specifically fungal and not of plant origin.20
Any sequences not passing this filter were removed. Taxonomy was assigned
to OTUs using UNITE.21 Samples were retained if they had at least 50 fungal
reads, and variance-stabilized transformations were used to normalize for differences in library depth and retain most samples.22

Statistical analyses
To relate clinical events with changes in season, generalized additive mixed
models and generalized additive models were fitted to identify significant
change throughout the year using the ‘mgcv’ package in R. For relationships
with respiratory illness and exacerbation, a generalized additive mixed model
was used with months as a spline and the option for a cyclic cubic regression
spline; exacerbation or respiratory illness events were the dependent variable,
and a logit regression was used. If 2 events occurred in the same month, only 1
event was noted. A random effect for subject was also included. This analysis
used a participant-month data set (around 1300 observations over 208 individuals). Analyses of virus infection were cross-sectional, where a cyclic cubic
regression spline was used for the dependent months variable, as well as logit
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regression on a participant level data set for each visit type, with the assumption that the lack of visit did not necessarily indicate the lack of virus infection.
Therefore, the ‘‘denominator’’ in the associated plot is the number of visits that
occurred within that month.
Analyses with microbiome, fungal, and transcriptome relationships were
analyzed similarly, except that the first principal coordinate (PC) was used as
the dependent variable in a Gaussian regression. When data were available for
fewer than 10 months, a smaller number of knots (evenly distributed cut points
between which a continuous curve is fitted to the data) were used in the
analysis. The estimated degrees of freedom statistic describes the nonlinearity
in the curve over time, with larger numbers representing greater variability in
the fitted line. Significant P values indicate the probability of a nonlinear trend.
Predicted values were obtained from the model using the ‘predict’ function
and represented using the ‘ggplot2’ package in R. To ensure model fit, we
reduced data for mixed models to months where individuals contributed at
least 5 days of observation. For associations with transcriptome modules,
the second principal coordinate was used, as the first was primarily explained
by differences in cell counts.10 To identify the specific bacteria, fungi, and
gene expression modules that related to the principal coordinate, Spearman
correlations were used and the correlation coefficient plotted.
Nasal bacterial and fungal microbiota distance matrices were calculated
using Bray Curtis and Canberra distance matrices, and bacterial microbiota
distance matrices were also calculated by Unweighted and Weighted UniFrac.
Bacterial and fungal distance matrices were calculated using ‘phyloseq’ in
R.23 Principal coordinates were calculated using the ‘ape’ package.
Permutational analyses of variance (PERMANOVA) were performed using
the ‘adonis2’ function from the ‘vegan’ package,24 and 999 permutations with
marginal tests (by 5 ‘‘margin’’), including exacerbation, virus detection, age,
sex, and study site in the same model. P < .05 was considered significant, with
trends being described at P <.1. Differentially abundant OTUs were identified
by DESeq2 in R,25 filtering to OTUs present in at least 10% of samples, and
using size factors calculated from positive counts and a local fit type. Relationships with age included additive adjustments for sex, study site, and season,
while season-specific outcome models also included adjustments for exacerbation and virus detection. P values were corrected for multiple comparisons
using the Benjamini-Hochberg correction, and false discovery rate–corrected
P < .2 was considered significant.
For analyses of OTU networks, nasal OTUs were filtered out if they were
present in less than 10% of samples, and correlations between OTUs were
identified using SparCC26 from the SpiecEasi package in R. A correlation of
0.5 or more indicated a connection, and networks were identified using a cluster_fast_greedy approach from the ‘igraph’ package,27 which uses the random
walker method. Nineteen networks were identified (see Table E5 in this article’s Online Repository at www.jacionline.org). To create a network-specific
OTU table, OTUs were collapsed by summing counts of OTUs within each
network for each sample. Any taxa that did not have any connections were
agglomerated into an ‘‘unassigned’’ network and are not presented in Table E5.
To delineate the specifics of these relationships in the context of season and
clinical outcomes, we examined associations of these networks with 4 transcriptome modules previously identified in this cohort, including those associated
with exacerbation (ie, epithelial mothers against decapentaplegic homolog 3
[SMAD3]-related cell differentiation, eosinophil activation, and mucus hypersecretion, extracellular matrix production, and EGFR signaling modules).
To identify instances where the combination of microbiota networks and
gene expression modules associated with distinct risk of subsequent
exacerbation, we utilized interaction terms in logistic regression models
with exacerbation as the dependent variable, and pairwise gene expression
modules and microbiome networks as interaction terms (ie, exacerbation ;
gene expression module 3 microbiome network). Interaction models are
adjusted for age, sex, and season. For these models, study site increased the
degrees of freedom, reduced the models’ ability to converge, and did not
change any effect estimates by more than 10%, and thus it was not used for
adjustments. Models with significant interaction terms were stratified by the
median count of the bacterial network to understand the nature of significant
interactions. In other words, in the context of a large abundance of a specific
microbiota network, a gene expression module is associated with the risk of
exacerbation. Interactions were considered significant if the P value for the
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overall interaction effect was less than .05 or if the P value for a specific median stratum was less than .05 with an overall interaction P value was less than
.1. Plots for visualization of interactions were developed using the ‘emmip’
function from the ‘emmeans’ package in R.28
Amplicon sequencing data sets generated and analyzed under the current
study are available in the European Nucleotide Archive under accession
number PRJEB42394. Transcriptomics data sets are available from the
original publication (PMID:30962590). Participant-level metadata are available upon request.

RESULTS
Clinical and upper airway microbiota features
covary with season
Relationships among season and clinical events, upper airway
microbiome, and nasal epithelial transcriptome were initially
assessed independently. Among 208 children with asthma
enrolled onto the study, a total of 164 respiratory illnesses and
143 exacerbations were reported. Consistent with previous
reports,7-9,29,30 incidence of respiratory illnesses and exacerbations exhibited seasonal trends (generalized additive mixed model
for respiratory illnesses; P < .001, Fig 1, A; P 5 .039, Fig 1, B),
with the highest frequency in fall and winter and the lowest frequency in the summer months. An increase in both respiratory illnesses and exacerbations was evident from late summer through
late fall. As expected, detection of any respiratory virus (picornavirus, coronavirus, influenza, or others) also varied by season; this
was true during baseline visits in the absence of illness (visit 0;
generalized additive model P 5 .012) and also during respiratory
illness events (visit 1a; P 5 .003; Fig 1, C). More specifically, in
respiratory illness samples, RV-A and RV-B, but not RV-C, exhibited significant seasonality (RV-A P 5 .015, RV-B P 5 .008,
Fig 1, D), peaking in late summer and fall.
Likewise, 16S rRNA nasal microbiota composition varied with
season in both baseline and respiratory illness samples (baseline
n 5 181, P 5 .001; respiratory illness n 5 97, P 5 .016, respectively, Fig 1, E). Distinct upper airway microbiota were evident
in late spring and early fall compared to other seasons, primarily
driven by increased relative abundance of multiple Moraxella
taxa in spring and several Staphylococcus in the fall (see Fig E1
in the Online Repository at www.jacionline.org). Upper airway
fungal microbiota did not relate to season in the absence of a respiratory illness (visit 0 n 5 108, P 5 .742, Fig 1, F). However, a
significant relationship between season and variation in fungal microbiota composition was observed in respiratory illness samples
(visit 1a n 5 57, P 5 .006, Fig 1, F). Illnesses experienced in the
spring associated with Malassezia enrichment, while those in the
fall were associated with enrichment of allergenic fungi, Candida,
and Cladosporium (see Fig E2 in the Online Repository).
Nasal transcriptomes were also assessed for relationships with
season within baseline and respiratory illness samples. For
baseline samples, a suggestion of variation throughout the year
did not quite reach statistical significance (visit 0 Principal Coordinate [PC] 2, P 5.071, n 5 94, Fig 1, G), though in the late spring
months, in parallel with elevated Moraxella abundance, increases
in chromatin modification, integrin, and keratinization modules
were evident (see Fig E3 in the Online Repository at www.
jacionline.org). Respiratory illnesses were associated with epithelial transcriptional modules related to antigen presentation (Fig
E3), although no association between season and epithelial transcription was identified in these samples (visit 1a PC2, P 5 .149,
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FIG 1. Variation in (A) respiratory illness (respiratory illness events as a proportion of total individuals
observed each month), (B) exacerbation (exacerbation events as a proportion of total individuals observed
each month), (C) virus detection (proportion of samples with detectable virus), (D) RV species during respiratory illness events, (E) nasal bacterial composition (16S rRNA, PC1), (F) mycobiome (ITS2, PC1), and (G)
nasal transcriptome (airway mucosal RNA-Seq, PC2) across seasons in baseline (visit 0) and respiratory
illness (visit 1a) samples. PC, Principal coordinate; ITS, Internal Transcribed Spacer; RV, Rhinovirus.

n 5 97, Fig 1, G), suggesting that host transcriptional response to
respiratory infection is relatively conserved across seasons. Relationships with PC1 were examined but did not reach statistical
significance and were primarily characterized by differences in
cell types (see Fig E4 in the Online Repository).

Baseline nasal microbiota relates to time to
respiratory illness
Consistent with previous reports,6 older children in this study
exhibited nasal enrichment of several Staphylococcus and Corynebacterium members, while younger children exhibited
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increased Moraxella, Haemophilus, and Alloiococcus taxa in
their baseline samples (n 5 181; Fig 2, A; see Table E1 in the Online Repository at www.jacionline.org). Among children with a
baseline sample, those who reported a first respiratory illness visit
did so between 3 and 202 days after the baseline visit (n 5 93).
While nasal bacterial microbiota composition at baseline was
not associated with the time to respiratory illness (Unweighted
UniFrac, PERMANOVA R2 5 0.014, P 5 .13, adjusted for age
and season of sampling), it was significantly associated with
time to exacerbation (Weighted UniFrac, R2 5 0.034, P 5 .04,
adjusted for age and season). These data indicate that age- and
season-adjusted analyses are necessary to reveal relationships between upper airway microbiota and length of time to exacerbation
in children with asthma.
Fungus composition at baseline (n 5 53) was primarily associated with the age of the child (Bray Curtis, PERMANOVA, R2 5
0.044, P 5 .001) after adjustment for exacerbation, virus detection, sex, and study site (P > .4 for all). Age-associated fungi
included a single Malassezia taxon (associated with older children) and distinct members of Ascochyta, Malassezia, Cladosporium, and Verticillium associated with younger-age participants
(Fig 2, B; see Table E2 in the Online Repository at www.
jacionline.org). This subset of children returned for a respiratory
illness visit between 5 and 192 days after the baseline visit, but
fungal communities at baseline were not associated with time to
first illness (Bray Curtis, PERMANOVA R2 5 0.021, P 5 .242;
after adjustment for age, study site, virus positivity, and season).
A single Cladosporium taxon (OTU8, the same Cladosporium
OTU associated with younger children in the study), was found
to be enriched in children who experienced a longer duration to
respiratory illness (OTU8 log2 fold change 5 0.106, false discovery rate–corrected P 5 .006), after adjustment for age, study site,
and season of sample collection.

Nasal microbiota during respiratory illness exhibits
season-specific relationships with clinical outcomes
Season-specific relationships with nasal microbiota, virus
detection, and exacerbations were observed in respiratory illness
samples. Specifically, nasal bacterial microbiota composition of
respiratory illness samples in the fall (n 5 34) associated with virus detection (Weighted UniFrac, PERMANOVA, R2 5 0.089,
P 5 .017) and with subsequent exacerbations (R2 5 0.078, P 5
.027) in a multivariable model that also included study site, age,
and sex (P > .2 for site, age, and sex; Table I). In the fall, bacteria
associated with respiratory illnesses and subsequent exacerbations included several Moraxella and Haemophilus members,
which were enriched both in virus-positive respiratory illnesses
and those that progressed to exacerbations (DESeq2, Fig 3, A
and B; see Tables E3 and E4 in the Online Repository at www.
jacionline.org). Nasal bacterial microbiota detected in respiratory
illnesses during winter (n 5 33) primarily covaried with virus
detection (Weighted UniFrac, PERMANOVA, R2 5 0.097, P 5
.008), study site (R2 5 0.325, P 5 .050), and age (R2 5 0.11,
P 5 .009), but not with exacerbations or child’s sex (P > .15 for
each; Table I) in a multivariable model. Relationships between
these variables and spring (n 5 22) or summer (n 5 8) upper
airway microbiota did not reach statistical significance, likely
as a result of the smaller sample sizes available during these seasons. Relationships using the same multivariable model and
including all samples were primarily related to age, with no
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significant relationships with exacerbation or virus infection
observed (Table I). Taken together, these data suggest that
season-specific bacterial interactions influencing respiratory
illness and exacerbations in children with asthma are strongest
in the fall.
During respiratory illnesses (n 5 58), fungal composition primarily associated with season (Bray Curtis; PERMANOVA; R2 5
0.076, P 5.008), and to a lesser extent age (R2 5 0.025, P 5.055).
Neither baseline nor illness fungal composition associated with
exacerbation risk.

Interactions between microbial networks and
immune transcriptional modules influence asthma
exacerbation risk
We next hypothesized that interactions between exacerbationassociated epithelial transcriptional modules and specific networks of cocolonizing microbes in the upper airways during
respiratory illness influence the risk of subsequent exacerbation in
a season-specific manner. Before this study, host transcriptional
modules from RNA-Seq of paired nasal lavage samples were
developed using weighted correlation network analysis; these
modules were found to discriminate viral and nonviral exacerbations.10 Because of our sample size, we focused specifically on the
4 host transcriptional modules previously found to be associated
with exacerbation events in this cohort:10 epithelial SMAD3related cell differentiation, eosinophil activation and mucus hypersecretion, extracellular matrix production, and epidermal
growth factor receptor signaling. Bacterial (16S rRNA) data
also underwent network analysis to reduce data dimensionality.
This process identified 19 bacterial networks (N1-19; Table
E5); interactions between these bacterial networks and the 4
exacerbation-associated transcriptome modules were assessed using logistic regression.
Seasonally adjusted analysis of respiratory illness samples
(n 5 97) revealed that SMAD3 interacted with 2 bacterial networks (N1 and N3) to significantly modify the risk of subsequent
exacerbation. N1 primarily comprised multiple Veillonella, Streptococcus, Neisseria, and Haemophilus OTUs (interaction P 5
.050), while N3 comprised entirely of Staphylococcus OTUs
(interaction P 5 .059). Specifically, increased expression of
SMAD3 among children with higher abundance of the N1 bacterial network was associated with increased exacerbation risk
(odds ratio [OR] 5 14.71, 95% confidence interval [CI] 5
1.50-144.14, P 5 .018; Fig 4, A, adjusted for age and season).
Children who possessed a reduced abundance of the N3 network
in the context of increased SMAD3 expression also exhibited
increased risk of exacerbation (OR 5 39.17, 95% CI 5 2.44626.48, P 5 .008, Fig 4, B, adjusted for age and season), suggesting that low abundance or loss of this nasal bacterial network may
promote exacerbation. Importantly, these 2 bacterial networks
were not inversely related or mutually exclusive (x2 P 5 .747).
When bacterial networks were not considered in the relationship
between SMAD3 and exacerbation, odds ratios were substantially
lower (OR 5 3.22, 95% CI 5 1.28-8.07, P 5 .01), and in interaction models unadjusted for season, interaction P values were
nonsignificant (P 5 .11 and .18). Thus, these findings provide evidence that interactions between specific upper airway microbial
networks and host transcriptional modules during respiratory
illness increase the risk of exacerbation in a season-specific
manner.
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A
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FIG 2. A, Specific bacterial taxa in baseline samples that associate with age (n 5 181). Moraxella and Haemophilus decrease in relative abundance with increasing age, while Corynebacterium and Staphylococcus
increase in abundance with increasing age. B, Fungus taxa in baseline samples related to age (n 5 53). Positive fold changes reflect taxa that increase with child’s age; negative fold changes, those that decrease with
increasing age. Data are color coded by genus-level taxon identity; circle size indicates average relative
taxon abundance. All findings are adjusted for sex, season of sample collection, and study site.

TABLE I. Variation in season-specific nasal microbiota during respiratory illness relates to clinical outcomes in children with
asthma using Weighted UniFrac distance
Overall (n 5 97)
Variable

Exacerbation
Virus positive
Age (years)
Study site
Sex

Fall (n 5 34)

Winter (n 5 33)

R2

P value

R2

P value

R2

P value

0.005
0.013
0.034
0.111
0.019

.747
.239
.017
.093
.093

0.078
0.089
0.025
0.151
0.036

.027
.017
.453
.785
.251

0.020
0.097
0.110
0.325
0.034

.455
.008
.009
.050
.194

R2 values and P values were obtained from multivariable PERMANOVA; multivariable PERMANOVA included all variables listed.

DISCUSSION
Seasonal variations in respiratory illnesses and asthma exacerbations are well described.4,31 Although asthma exacerbations
occur throughout the year, they are most common in the fall, an
observation validated in this cohort of inner-city children with
asthma. While this pattern has traditionally been attributed to
increased virus exposure after returning to school,32 there are a
number of other potential contributing factors to this seasonal
variation. Human behavior covaries with season, including the
proportion of time spent indoors and in close proximity to others,
increasing the potential for horizontal transmission of cellular microbes as well as viruses. In parallel, atmospheric,33 human, and
animal microbiomes also exhibit seasonal variation,34,35 as do
several respiratory viruses.36-38 The latter is consistent with observations made in this cohort, which indicate increased RV
detection in late summer which peaks in fall and comprises successional waves of RV-A, -B, and -C.
Conditions in the upper airway also covary with seasonal
changes in humidity, temperature, air pollution, allergen exposure, and virus infection.39 In this analysis, while upper airway
transcriptional response to respiratory illness was relatively
conserved, transcriptional variation in baseline samples was associated with season, particularly summer, when modules involved

in keratinization and integrins were expressed. Given that this
season exhibits low rates of respiratory illness and exacerbation,
it is possible these season-specific host responses protect against
virus infection. An alternative possibility is that these transcriptional changes in the summer in children with asthma influence
their upper airway microbiome and increase susceptibility to subsequent virus encounters in the late summer and fall season. Yet
another possibility is that upper airway microbiota responds to
the external environment, including pollution40 and temperature.41 One recent publication identified thermo-sensing abilities
in S pneumoniae and H influenzae leading to altered expression of
virulence factors under distinct temperature conditions.41 Seasonal variation in nasal microbiota composition, especially in infants and children, has previously been described,7,9,29,30 and the
types of bacteria present in the upper airways during the fall season relate to risk of respiratory illness and exacerbation in children with asthma.6
These observations raised the possibility that the upper airway
microbiome and microbial exposures may dynamically interact
with each other and the host in a season-specific manner to
influence respiratory illness susceptibility and exacerbation outcomes in children with asthma. This prompted an examination of
microbiome features in season-specific and -adjusted analyses
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A
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FIG 3. Specific bacterial taxa in fall respiratory illness samples (n 5 34) relate to (A) subsequent exacerbation and (B) virus infection. Taxa are color coded by genus-level taxon identity; circle size indicates average
relative taxon abundance. All findings are adjusted for exacerbation, virus infection, sex, season of sample
collection, and study site.
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FIG 4. Interactions between SMAD3 expression and 2 upper airway bacterial networks (N1 and N3) during
respiratory illness events significantly increases the probability of subsequent exacerbation (age, sex and
season of respiratory illness adjusted analysis). A, Interaction between SMAD3 expression and elevated
abundance of the N1 bacterial network increases risk of exacerbation. B, Interaction between SMAD3
expression and reduced abundance of the N3 bacterial network increases risk of exacerbation. Slopes indicate the association between exacerbation and SMAD3 expression among subsets of children differentiated
by the median count of reads in each network, with 4558 reads in (A) and 7949 reads in (B).

that associated with respiratory illness and subsequent exacerbation. Fall respiratory illness microbiota were enriched for Haemophilus and Moraxella in the context of both virus infection and
subsequent exacerbation, which is consistent with our previous

study that longitudinally profiled the upper airway bacterial microbiota of over 400 children with asthma specifically during
the fall season.6 Thus, the presence of specific bacterial genera
in the upper airway microbiota during fall respiratory illnesses
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increased the likelihood of subsequent exacerbation and virus
detection, suggesting that their interaction with host response to
virus infection relate to these outcomes.
Host transcriptome analyses provide insights into the host
response during respiratory illnesses and subsequent exacerbations. Our data indicate that combining this information with
networks of coassociated bacteria in season-adjusted interaction
models permits identification of children at significantly higher
risk of asthma exacerbation. Specifically, those possessing a
network of Streptococcus, Haemophilus, Neisseria, Prevotella,
and other genera (N1) or those lacking a Staphylococcus network
(N3) were found to have increased risk of exacerbation associated
with increased epithelial SMAD3-related cell differentiation module expression. Although causative directionality is currently unknown, the SMAD3 module is composed of several genes
including RRAD42 and TRPV443 that regulate the uptake of calcium. Previous studies have demonstrated that Staphylococcus
aureus forms less-structured biofilms with increasing calcium
availability44,45 and that calcium improves macrophage response
to H influenzae.46 Additionally, the SMAD3 module also includes
the CLU gene, which encodes clusterin, a protein associated with
cellular debris clearance.47 Intriguingly, independent studies have
shown that clusterin binds efficiently to S aureus,48 improving
species-specific bacterial adhesion and reducing the bacteria
load required to produce a pathogenic response. These findings
support the hypothesis that specific upper airway bacterial networks may leverage host responses to alter their abundance and
pathogenicity in the upper airways of children with asthma,
thus enhancing disease activity and risk of subsequent
exacerbation.
This study provides initial insights into specific host–microbe
interactions in the upper airways that promote exacerbation.
Legacy effects of these interactions imprinted via epigenetic
modifications in key immune cell populations poses a plausible
mechanism for the chronicity of asthma. Indeed, previous studies
have identified methylation patterns associated with T-cell
maturation, TH2 immunity, and oxidative stress (a key antimicrobial response) in children with asthma,49 providing data that
epigenetic marks in these children relate to asthma development.
The role of DNA methylation in the differentiation and function
of Treg cells is also well described,50,51 and in parallel, a recent
study found that gut bacteria with enhanced methylation
signatures exhibit greater Treg cell induction.52 How asthmaassociated epigenetic modifications in the upper airways are influenced by interactions with colonizing microbes remains unknown
but is an active area of new and potentially fruitful research.
While this analysis provides important insights into seasonal
variation the upper airway microbiome and its relationship with
respiratory illnesses and exacerbations, there are a few limitations
to consider. First, children enrolled onto the MUPPITS-1 study
reside in urban environments and had active asthma; as such,
these findings may not be generalizable to a broader population.
Also, the number of samples with bacterial and fungal data
available for respiratory illness events, especially those in specific
seasons, was limited; a larger sample size may further elucidate
these interactions. The study also leveraged DNA amplicon–
based microbiota profiles providing information on which
microbes exist in the upper airways, limiting our ability to assess
microbial activities that relate to increased exacerbation risk.
However, the use of RNA-based microbiome analyses to capture

transcriptionally active microbes on the upper airway mucosal
surface should offer a more accurate view of microbial activities
that relate to host immune responses and clinical outcomes. In
addition, dual RNA-Seq, capturing both host and microbial
transcriptional activity in parallel, could greatly enhance our
understanding of the relationships we described. Finally, our
findings surrounding microbe–host interactions are correlative
and do not prove causality; further studies deconstructing these
interactions to delineate mechanisms that govern susceptibility to
respiratory infection and exacerbation are clearly required.
These findings indicate that age and seasonal dynamics in
upper airway microbiomes represent important factors to
consider in analyses of respiratory microbiomes. The study also
identifies specific networks of upper airway microbes that interact
with host transcriptional responses to significantly increase risk of
subsequent exacerbation and that this relationship is also strongly
dependent on season. Therefore, host responses in concert with
cooperative networks of airway-associated bacteria may promote
exacerbation in a season-dependent manner.
We thank the patients and parents of those enrolled onto the Inner-City
Asthma Consortium, whose participation made this study possible. We thank
all of the investigators and staff of the National Institute of Allergy and
Infectious Diseases’ Inner-City Asthma Consortium.

Key messages
d

Asthma exacerbation, respiratory illness, virus infection,
RV species, and upper airway microbiota composition
all exhibit seasonal dynamics.

d

During fall respiratory illnesses, nasal microbiota composition relates to exacerbation and virus infection.

d

Specific networks of upper airway bacteria present during respiratory illness interact with a host gene expression
module to increase risk of exacerbation, suggesting that
exacerbation risk associated with gene expression may
be microbiome dependent.
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